Skip to Content

    In 1994, few of China’s legions of diabetics—the nation has 96.3 million today compared with 26 million in the U.S.—received regular insulin treatments. That’s when Danish drugmaker Novo Nordisk committed to tackling diabetes in China—an effort that involved training tens of thousands of physicians, educating patients, and investing in local manufacturing and R&D. The results? A 2011 research paper estimated that the efforts had saved 140,000 life-years from diabetes-related complications. Novo, meanwhile, has a 63% market share in China.

    Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

    Company Info

    Sector
    Health Care
    Industry
    Pharmaceuticals
    Country
    Denmark
    Revenues ($ millions)15,802
    Company type
    Public
    CEO
    Lars Rebien Sørensen
    Websitehttp://www.novonordisk.com
    Impact Segment
    Public Health/Nutrition

    Fortune Rankings

    Fortune 500 Rank-
    Fortune 500 Profile-
    Most Powerful Women Rank-
    Most Powerful Women Profile-
    World's Greatest Leaders Rank-
    World's Greatest Leaders Profile-